Objectives: Early-onset psychoses (EOP) vary considerably with regard to diagnostic stability and functional outcome. The aim of this study was the assessment of executive dysfunction as a predictor of outcome in EOP. Method: This was a retrospective cohort study. Twenty-five hospitalized patients with non-affective EOP were assessed with the Wisconsin Card Sorting Test (WCST) during the index admission. Associations with current diagnosis, further admissions, current treatment status and occupational and relationship outcome were analyzed in 6 years of follow-up. Results: The mean age at the index admission and the follow-up was 16.1 ± 1.35 and 22.0 ± 2.1 years, respectively. After discharge, almost all subjects (96%) at least briefly continued psychiatric treatment, and the majority of them (76%) were readmitted. Worse baseline WCST results were associated with a follow-up schizophrenia diagnosis, being a psychiatric in- or outpatient at the moment of follow-up assessment and receiving psychotropic medication. A low number of completed categories correlated with receiving a disability pension at the follow-up. Conclusion: In patients with EOP, baseline executive function impairment was associated with schizophrenia diagnosis and psychiatric treatment at the follow-up. The association between baseline results and psychiatric treatment may explain the limited effect of baseline impairment on follow-up occupational and relationship status.

Keywords:
Psychosis, Executive functions, Outcome, Differential diagnosis, Antipsychotics
1.
Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R: Is adolescent-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 2005;44:782-789.
2.
McClellan J, McCurry C: Early onset psychotic disorders: diagnostic stability and clinical characteristics. Eur Child Adolesc Psychiatry 1999;8(suppl 1):I13-I19.
3.
Fraguas D, de Castro MJ, Medina O, Parellada M, Moreno D, Graell M, et al: Does diagnostic classification of early-onset psychosis change over follow-up? Child Psychiatry Hum Dev 2008;39:137-145.
4.
Valevski A, Ratzoni G, Sever J, Apter A, Zalsman G, Shiloh R, et al: Stability of diagnosis: a 20-year retrospective cohort study of Israeli psychiatric adolescent inpatients. J Adolesc 2001;24:625-633.
5.
Castro-Fornieles J, Baeza I, de la Serna E, Gonzalez-Pinto A, Parellada M, Graell M, et al: Two-year diagnostic stability in early-onset first-episode psychosis. J Child Psychol Psychiatry 2011;52:1089-1098.
6.
Clemmensen L, Vernal DL, Steinhausen H-C: A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 2012;12:150.
7.
Rabinowitz J, Levine SZ, Häfner H: A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res 2006;88:96-101.
8.
Langeveld J, Joa I, Friis S, ten Velden Hegelstad W, Melle I, Johannessen JO, et al: A comparison of adolescent- and adult-onset first-episode, non-affective psychosis: 2-year follow-up. Eur Arch Psychiatry Clin Neurosci 2012;262:599-605.
9.
Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M: Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode pa- tients. Schizophr Res 2007;95:1-8.
10.
Amminger GP, Henry LP, Harrigan SM, Harris MG, Alvarez-Jimenez M, Herrman H, et al: Outcome in early-onset schizophrenia revisited: findings from the Early Psychosis Prevention and Intervention Centre long-term follow-up study. Schizophr Res 2011;131:112-119.
11.
Jarbin H, von Knorring A-L: Diagnostic stability in adolescent onset psychotic disorders. Eur Child Adolesc Psychiatry 2003;12:15-22.
12.
Correll CU, Smith CW, Auther AM, McLaughlin D, Shah M, Foley C, et al: Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia. J Child Adolesc Psychopharmacol 2008;18:475-490.
13.
Zabala A, Rapado M, Arango C, Robles O, de la Serna E, González C, et al: Neuropsychological functioning in early-onset first-episode psychosis: comparison of diagnostic subgroups. Eur Arch Psychiatry Clin Neurosci 2010;260:225-233.
14.
Fagerlund B, Pagsberg AK, Hemmingsen RP: Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders. Schizophr Res 2006;85:30-39.
15.
McClellan J, Prezbindowski A, Breiger D, McCurry C: Neuropsychological functioning in early onset psychotic disorders. Schizophr Res 2004;68:21-26.
16.
Agid O, Siu CO, Pappadopulos E, Vanderburg D, Remington G: Early prediction of clinical and functional outcome in schizophrenia. Eur Neuropsychopharmacol 2013;23:842-851.
17.
Oie M, Sundet K, Ueland T: Neurocognition and functional outcome in early-onset schizophrenia and attention-deficit/hyperactivity disorder: a 13-year follow-up. Neuropsychology 2011;25:25-35.
18.
Cervellione KL, Burdick KE, Cottone JG, Rhinewine JP, Kumra S: Neurocognitive deficits in adolescents with schizophrenia: longitudinal stability and predictive utility for short-term functional outcome. J Am Acad Child Adolesc Psychiatry 2007;46:867-878.
19.
Jarbin H, Ott Y, Von Knorring A-L: Adult outcome of social function in adolescent-onset schizophrenia and affective psychosis. J Am Acad Child Adolesc Psychiatry 2003;42:176-183.
20.
Remberk B, Bażyńska AK, Krempa-Kowalewska A, Rybakowski F: Adolescent insanity revisited: course and outcome in early-onset schizophrenia spectrum psychoses in an 8-year follow-up study. Compr Psychiatry 2014;55:1174-1181.
21.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic Criteria for Research. Geneva, World Health Organization, 1993.
22.
Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G: Wisconsin Card Sorting Test Manual. Odessa, Psychological Assessment Resources, 1993.
23.
Remberk B, Namysłowska I, Rybakowski F: Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:348-354.
24.
SPSS package v. 18.0 for Windows. Statistical Package for Social Sciences. Chicago, SPSS Inc, 2009.
25.
Remberk B, Bogumił B, Namysłowska I: Retrospective analysis of the course of psychotic episodes in adolescent inpatients. Psychiatr Pol 2012;46:511-521.
26.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, DSM-IV TR. Washington, American Psychiatric Association, 2000.
27.
Lin A, Wood SJ, Nelson B, Brewer WJ, Spiliotacopoulos D, Bruxner A, et al: Neurocognitive predictors of functional outcome two to 13 years after identification as ultra-high risk for psychosis. Schizophr Res 2011;132:1-7.
28.
Kim HS, Shin NY, Jang JH, Kim E, Shim G, Park HY, et al: Social cognition and neurocognition as predictors of conversion to psychosis in individuals at ultra-high risk. Schizophr Res 2011;130:170-175.
29.
Nuechterlein KH, Subotnik KL, Green MF, Ventura J, Asarnow RF, Gitlin MJ, et al: Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull 2011;37(suppl 2):S33-S40.
30.
Ventura J, Subotnik KL, Guzik LH, Hellemann GS, Gitlin MJ, Wood RC, et al: Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 2011;132:18-23.
31.
Remschmidt H, Martin M, Fleischhaker C, Theisen FM, Hennighausen K, Gutenbrunner C, et al: Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm 2007;114:505-512.
32.
Röpcke B, Eggers C: Early-onset schizophrenia: a 15-year follow-up. Eur Child Adolesc Psychiatry 2005;14:341-350.
33.
Robles O, Zabala A, Bombín I, Parellada M, Moreno D, Ruiz-Sancho A, et al: Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis. Schizophr Bull 2011;37:405-415.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.